How deadly is seasonal influenza associated pneumonia? The German Competence Network for Community-acquired pneumonia (CAPNETZ).
Summary of "How deadly is seasonal influenza associated pneumonia? The German Competence Network for Community-acquired pneumonia (CAPNETZ)."
The emergence of new influenza virus subtypes has rekindled the interest in the clinical course and outcome of patients with influenza-associated pneumonia. Based on prospective data from 5032 patients with CAP included in the German CAP-Competence Network (CAPNETZ), we studied the incidence, clinical characteristics, and outcome of patients with influenza-associated CAP and compared these to patients without influenza. Diagnosis relied on a positive PCR for influenza in throat washings. 160 patients with influenza-associated CAP were identified (3,2% of total population, 12% of those with defined etiology). 34 patients (21%) with seasonal influenza had a concomitant pathogen (mostly S. pneumoniae). Patients with influenza associated CAP were significantly older, had been less often vaccinated, and had less often preceding antibacterial treatment. Thirty-day mortality was low (4.4%), not different to that of patients with pneumonia caused by bacterial (6.2%) or viral other than influenza pathogen (4%). Patients with influenza plus a bacterial pathogen (mixed influenza-associated pneumonia) had a higher mortality than those with pure influenza associated pneumonia (9% vs 3.2%). Mortality was higher in patients with mixed as compared to pure influenza associated pneumonia. However, we could not observe any excess mortality in patients with influenza associated pneumonia.
Affiliation
Ulm University Hospital Germany.
Journal Details
This article was published in the following journal.
Name: The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology
ISSN: 1399-3003
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20817703
- DOI: http://dx.doi.org/10.1183/09031936.00037410
Medical and Biotech [MESH] Definitions
Influenza B Virus
Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.
Hemagglutinin Glycoproteins, Influenza Virus
Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.
Influenza In Birds
Infection of domestic and wild fowl and other BIRDS with INFLUENZA A VIRUS. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic POULTRY.
Pneumonia, Lipid
Pneumonia due to aspiration or inhalation of various oily or fatty substances.
Pneumonia, Rickettsial
Pneumonia caused by infection with bacteria of the family RICKETTSIACEAE.
PubMed Articles
Please cite this paper as: Song et al. (2011). Clinical, laboratory and radiologic characteristics of 2009 pandemic influenza A/H1N1 pneumonia: primary influenza pneumonia versus concomitant/secondar...
Estimates of deaths associated with seasonal influenza --- United States, 1976--2007.
Influenza infections are associated with thousands of deaths every year in the United States, with the majority of deaths from seasonal influenza occurring among adults aged =65 years. For several dec...
Abstract In this article we review the clinical characteristics and computed tomography (CT) findings in children with 2009 pandemic H1N1 influenza viral pneumonia. The medical charts of 88 children w...
CONTEXT: The clinical characteristics of pandemic 2009 influenza A(H1N1) infections have not been compared directly with illnesses caused by other influenza A strains. OBJECTIVE: To compare clinical f...
The need for quadrivalent vaccine against seasonal influenza.
Seasonal influenza epidemics represent a substantial public health burden, causing significant morbidity and mortality. Influenza in humans can be caused by influenza type A and type B viruses, and al...
Clinical Trials
Phase IV Clinical Trial of an Influenza Split Vaccine Anflu
To evaluate the safety and immunogenicity of the three consecutive lots of an seasonal split influenza vaccine Anflu in adults, a randomized, double-blind and controlled clinical trial was...
This is a trial for annual registration of the updated seasonal influenza vaccine formulation.
Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011
The seasonal influenza vaccination program for 2010-2011 will be the first to follow the H1N1 pandemic of 2009. Many Canadians either had the H1N1 infection or the adjuvanted H1N1 vaccine....
This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007 infl...
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
Every year the human population suffers from seasonal outbreaks of influenza resulting in both illness and death. However, the rates of illness and death from seasonal outbreaks are signif...
